Your Article Summary
See Latest ArticlesFDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Corporate News Releases - The Healthcare Sales & Marketing Network, 12/02/08
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Cerner Enters R&D Pact with University
HealthDataManagement, 12/08/09
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma
Bristol Myers-Squibb Company, 12/08/09